Trimethoprim/sulfamethoxazole

Trimethoprim/sulfamethoxazole

Trimethoprim (top) and sulfamethoxazole (bottom)
Combination of
Sulfamethoxazole	Sulfonamide antibiotic
Trimethoprim	Dihydrofolate reductase inhibitor
Clinical data
Trade names	Bactrim, Cotrim, Septra, others
Other names	TMP/SMX, Co-trimoxazole (BAN UK)
AHFS/Drugs.com	Monograph
License data	US DailyMed: Sulfamethoxazole trimethoprim
Pregnancy category	AU: C
Routes of administration	By mouth, intravenous
ATC code	J01EE01 (WHO) J04AM08 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Identifiers
CAS Number	8064-90-2
PubChem CID	358641
ChemSpider	318412
KEGG	D00285
ChEBI	CHEBI:3770
ChEMBL	ChEMBL58061
CompTox Dashboard (EPA)	DTXSID0032233
(verify)

Trimethoprim/sulfamethoxazole, (also known as Cotrimoxazole) sold under the brand name Bactrim among others, is a fixed-dose combination antibiotic medication used to treat a variety of bacterial infections. It consists of one part trimethoprim to five parts sulfamethoxazole. It is used to treat urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, and cholera, among others. It is used both to treat and prevent pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and other causes of immunosuppression. It can be given by mouth or intravenously.

Trimethoprim/sulfamethoxazole is on the World Health Organization's List of Essential Medicines and is also available as a generic medication. In 2020, it was the 121st most commonly prescribed medication in the United States, with more than 5 million prescriptions.

Medical uses

Pneumocystis jirovecii pneumonia

Trimethoprim/sulfamethoxazole (TMP/SMX) is the medicine most commonly used to prevent Pneumocystis jirovecii pneumonia (PCP) People who get Pneumocystis pneumonia have a medical condition that weakens their immune system, like HIV/AIDS, or take medicines (such as corticosteroids) that reduce the body's ability to fight bacterial and viral infections. People with HIV/AIDS are less likely to get Pneumocystis pneumonia as a result of antiretroviral therapy (ART). However, Pneumocystis pneumonia is still a substantial public health problem. Most of what is scientifically known about Pneumocystis pneumonia and its treatment comes from studying people with HIV/AIDS.

Susceptibility

Organisms against which trimethoprim/sulfamethoxazole can be effective include:

The only notable nonsusceptible organisms are Pseudomonas aeruginosa, the mycoplasmae and Francisella tularensis (the causative organism of tularaemia).

Pregnancy and breast feeding

Its use during pregnancy is contraindicated, although it has been placed in Australian pregnancy category C. Its use during the first trimester (during organogenesis) and 12 weeks prior to pregnancy has been associated with an increased risk of congenital malformations, especially malformations associated with maternal folic acid deficiency (which is most likely related to the mechanism of action of co-trimoxazole) such as neural tube defects such as spina bifida, cardiovascular malformations (e.g. Ebstein's anomaly), urinary tract defects, oral clefts, and club foot in epidemiological studies. Its use later on during pregnancy also increases the risk of preterm labour (odds ratio: 1.51) and low birth weight (odds ratio: 1.67). Animal studies have yielded similarly discouraging results.

It appears to be safe for use during breastfeeding as long as the baby is healthy.

Babies

Its use in those less than 2 months of age is not recommended due to the risk of adverse side effects.

Adverse effects

Common side effects include nausea, vomiting, rash, and diarrhea. Severe allergic reactions and Clostridium difficile infection may occasionally occur. Its use in pregnancy is not recommended. It appears to be safe for use during breastfeeding as long as the baby is healthy. Trimethoprim/sulfamethoxazole generally results in bacterial death. It works by blocking the making and use of folate by the microorganisms.

Contraindications

Contraindications include the following:

Interactions

Its use is advised against in people being concomitantly treated with:

Overdose

Likely signs of toxicity include:

The recommended treatment for overdose includes:

• Administration of activated charcoal
• Stomach pumping
• General supportive measures
• Haemodialysis, which is moderately effective in clearing co-trimoxazole from the plasma.
• Calcium folinate treatment in cases of blood dyscrasias
• Forcing oral fluids

Alkalinisation of the urine may reduce the toxicity of sulfamethoxazole, but it may increase the toxic effects of trimethoprim.

Pharmacology

Tetrahydrofolate synthesis pathway

The synergy between trimethoprim and sulfamethoxazole was first described in the late 1960s. Trimethoprim and sulfamethoxazole have a greater effect when given together than when given separately, because they inhibit successive steps in the folate synthesis pathway. They are given in a one-to-five ratio in their tablet formulations so that when they enter the body their concentration in the blood and tissues is roughly one-to-twenty — the exact ratio required for a peak synergistic effect between the two.

Sulfamethoxazole, a sulfonamide, induces its therapeutic effects by interfering with the de novo (that is, from within the cell) synthesis of folate inside microbial organisms such as protozoa, fungi and bacteria. It does this by competing with p-aminobenzoic acid (PABA) in the biosynthesis of dihydrofolate.

Trimethoprim serves as a competitive inhibitor of dihydrofolate reductase (DHFR), hence inhibiting the de novo synthesis of tetrahydrofolate, the biologically active form of folate.

Tetrahydrofolate is crucial in the synthesis of purines, thymidine, and methionine which are needed for the production of DNA and proteins during bacterial replication. Thus the net effect of each of these drugs is a bacteriostatic halt in replication. When combined, TMP and SMX are bactericidal.

The effects of trimethoprim causes a backlog of dihydrofolate (DHF) and this backlog can work against the inhibitory effect the drug has on tetrahydrofolate biosynthesis. This is where the sulfamethoxazole comes in; its role is in depleting the excess DHF by preventing it from being synthesised in the first place.

Co-trimoxazole was claimed to be more effective than either of its components individually in treating bacterial infections, although this was later disputed. Because it has a higher incidence of adverse effects, including allergic responses, its use has been restricted in many countries to very specific circumstances where its improved efficacy has been demonstrated. It may be effective in a variety of upper and lower respiratory tract infections, kidney and urinary tract infections, gastrointestinal tract infections, skin and wound infections, sepsis, and other infections caused by sensitive organisms. Co-trimoxazole decreases the risk of recurrence of retinochoroiditis. The global problem of advancing antimicrobial resistance has led to a renewed interest in the use of co-trimoxazole more recently.

Society and culture

Legal status

Indications for co-trimoxazole

Indication	FDA-labelled indication?	TGA-labelled indication?	MHRA-labelled indication?	Literature support
Acute infective exacerbation of COPD	Yes	No	No	Clinical trials are lacking.
Prophylaxis in HIV-infected individuals	No	No	No	Effective in one Ugandan study on morbidity, mortality, CD4-cell count, and viral load in HIV infection.
Otitis media	Paediatric population only	No	Yes	Clinical trials have confirmed its efficacy in chronic active otitis media and acute otitis media.
Travellers' diarrhoea, treatment & prophylaxis	Yes	No	No	Clinical trials have confirmed its efficacy as a treatment for travellers' diarrhoea.
Urinary tract infection	Yes	No	Yes	Clinical trials have confirmed its efficacy in this indication.
Bacterial infections
Acne vulgaris	No	No	No	At least one clinical trial supports its use in this indication.
Listeria	No	Yes	No	Well-designed clinical trials are lacking.
Melioidosis	No	Yes	No	Clinical trials have confirmed its efficacy, with or without adjunctive doxycycline; although, co-trimoxazole alone seems preferable.
Pertussis (whooping cough)	No	No	No	One cochrane review supports its efficacy in preventing the spread of pertussis.
Shigellosis	Yes	Yes	No	Generally accepted treatment for shigellosis. A recent Cochrane review found that while it is an effective treatment for shigellosis it also produces more significant adverse effects than other antibiotic drugs.
Staphylococcus aureus infections	No	No	No	In vitro and in vivo activity against both non-resistant and methicillin-resistant Staphylococcus aureus (MRSA) infections.
Tuberculosis	No	No	No	In vitro and in vivo activity against both nonresistant and MDR strains of TB.
Whipple's disease	No	No	No	Co-trimoxazole is the recommended standard treatment for whipple's disease in some treatment protocols.
Fungal and protozoal infections
Isosporiasis	No	No	No	Clinical trials have confirmed its use in this indication.
Malaria	No	No	No	Clinical trials have confirmed its efficacy in both the treatment and prevention of malaria.
Pneumocystis jirovecii pneumonia	Yes	Yes	Yes	Its use as a prophylactic treatment is supported by one clinical trial involving children with acute lymphoblastic leukaemia. Other than this and one other clinical trial into its efficacy as a treatment for pneumocystis pneumonia, data on its use in both the treatment and prevention of pneumocystis pneumonia is significantly lacking.
Toxoplasmosis	Yes	Prevention only	Yes	Clinical trials have confirmed its prophylactic and therapeutic utility in cases of toxoplasmosis.

Trade names

Trimethoprim/sulfamethoxazole may be abbreviated as SXT, SMZ-TMP, TMP-SMX, TMP-SMZ, or TMP-sulfa.

Co-trimoxazole (British Approved Name (BAN)) is manufactured and sold by many different companies. The following list of brand names is incomplete:

Economics

Trimethoprim/sulfamethoxazole is relatively inexpensive as of 2019.

External links

• "Sulfamethoxazole mixture with trimethoprim". Drug Information Portal. U.S. National Library of Medicine.